Clinical Trial Update: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating topical HT-001 for treating EGFR inhibitor–related skin toxicities (acneiform eruption, xerosis cutis, and paronychia); curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acneiform Eruption
• Paronychia
• Xerosis Cutis

Drugs mentioned

• HT-001

Snippet

Sponsor: Hoth Therapeutics, Inc. | Conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis | Phase 2 | Status: RECRUITING